Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.

Aoun F, Bourgi A, Ayoub E, El Rassy E, van Velthoven R, Peltier A.

Ther Adv Urol. 2017 Mar 1;9(3-4):73-80. doi: 10.1177/1756287217697661. eCollection 2017 Mar-Apr. Review.

2.

The role of chemotherapy and new targeted agents in the management of primary prostate cancer.

Kumar SS, Pacey S.

J Clin Urol. 2016 Dec;9(2 Suppl):30-37. doi: 10.1177/2051415816685211. Epub 2016 Dec 1.

3.

An audit of referral and treatment patterns of high-risk prostate cancer patients in Alberta.

Alghamdi M, Taggar A, Tilley D, Kerba M, Kostaras X, Gotto G, Sia M.

Can Urol Assoc J. 2016 Nov-Dec;10(11-12):410-415. doi: 10.5489/cuaj.3910.

4.

Biochemical Recurrence Prediction in High-Risk Prostate Cancer Patients, Following Robot-Assisted Radical Prostatectomy.

Yamaguchi N, Yumioka T, Iwamoto H, Masago T, Morizane S, Honda M, Sejima T, Takenaka A.

Yonago Acta Med. 2016 Dec 26;59(4):288-295. eCollection 2016 Dec.

6.

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.

Pham T, Sadowski MC, Li H, Richard DJ, d'Emden MC, Richard K.

Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. eCollection 2015. Review.

7.

Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies.

Juloori A, Shah C, Stephans K, Vassil A, Tendulkar R.

Prostate Cancer. 2016;2016:2420786. doi: 10.1155/2016/2420786. Epub 2016 May 23. Review.

8.

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.

Merseburger AS, Hupe MC.

Adv Ther. 2016 Jul;33(7):1072-93. doi: 10.1007/s12325-016-0351-4. Epub 2016 May 31. Review.

9.

A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials.

Geifman N, Butte AJ.

Sci Data. 2016 May 10;3:160027. doi: 10.1038/sdata.2016.27.

10.

Radiotherapy and Hormone Treatment in Prostate Cancer.

Böhmer D, Wirth M, Miller K, Budach V, Heidenreich A, Wiegel T.

Dtsch Arztebl Int. 2016 Apr 8;113(14):235-41. doi: 10.3238/arztebl.2016.0235.

11.

Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Abusamra A, Murshid E, Kushi H, Alkhateeb S, Al-Mansour M, Saadeddin A, Rabah D, Bazarbashi S, Alotaibi M, Alghamdi A, Alghamdi K, Alsharm A, Ahmad I.

Urol Ann. 2016 Apr-Jun;8(2):123-30. doi: 10.4103/0974-7796.176872. Review.

12.

MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.

Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA.

Neoplasia. 2016 Apr;18(4):213-22. doi: 10.1016/j.neo.2016.01.006.

13.

Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma.

Baker CB, McDonald AM, Yang ES, Jacob R, Rais-Bahrami S, Nix JW, Fiveash JB.

Prostate Cancer. 2016;2016:2674954. doi: 10.1155/2016/2674954. Epub 2016 Mar 9.

14.

Fortifying the Treatment of Prostate Cancer with Physical Activity.

Champ CE, Francis L, Klement RJ, Dickerman R, Smith RP.

Prostate Cancer. 2016;2016:9462975. doi: 10.1155/2016/9462975. Epub 2016 Feb 10. Review.

15.
16.

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.

Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M 3rd, Gottschalk AR.

Radiat Oncol. 2016 Jan 21;11:8. doi: 10.1186/s13014-016-0585-y.

17.
18.

Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.

Habl G, Katayama S, Uhl M, Kessel KA, Edler L, Debus J, Herfarth K, Sterzing F.

BMC Cancer. 2015 Nov 7;15:868. doi: 10.1186/s12885-015-1886-5.

19.

Integrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?

Goineau A, d'Aillières B, de Decker L, Supiot S.

Front Oncol. 2015 Oct 15;5:227. doi: 10.3389/fonc.2015.00227. eCollection 2015. Review.

20.

Cardiovascular effects of hormone therapy for prostate cancer.

Lester JF, Mason MD.

Drug Healthc Patient Saf. 2015 Jul 23;7:129-38. doi: 10.2147/DHPS.S50549. eCollection 2015. Review.

Supplemental Content

Support Center